Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Environmental, Social & Governance
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Bone Marrow Conditioning
    • Clinical Trials
    • Illuccix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
    • Investor Centre
    • Financial Reports & Presentations
    • Corporate Governance
    • ASX Announcements
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News & Views

News & Views

News & Views

Telix and Cyclotek Conclude Radiopharmaceutical Manufacturing Agreement for Australia and New Zealand

ASX, News,

Telix is pleased to announce the completion of a Master Services Agreement with Cyclotek (Aust) Pty Ltd…

Read more

Abzena and Telix Sign Licence Agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies

ASX, News,

Telix is pleased to announce a licence agreement collaboration with Abzena plc (Abzena) for its prostate-specific membrane antigen antibodies…

Read more

Telix Pharmaceuticals and Atlab Pharma Conclude Therapeutic Product Development Agreement for Prostate Cancer

ASX, News,

Telix is pleased to announce the completion of a product collaboration and purchase option agreement with Atlab Pharma SAS…

Read more

Telix Pharmaceuticals Acquires Glioblastoma Program from Therapeia

ASX, News,

Telix is pleased to announce a product development partnership with Therapeia GmbH & Co KG…

Read more

Wilex Signs Antibody License Agreement With Telix Pharmaceuticals Limited

News,

Telix is delighted to have established this licensing agreement with Wilex for an important product with the potential to significantly impact cancer…

Read more
1 … 25 26 27

Subscribe

* indicates required
Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings

Recent legislative changes to the Corporations Act 2001 (Cth), which came into effect on 1 April 2022, mean there are new options available to shareholders as to how you elect to receive your communications from Telix. Telix will no longer send shareholders physical meeting documents unless you request a copy to be mailed.

Telix encourages shareholders to provide your email address so we can communicate with you electronically when shareholder notices become available online for such items as meeting documents, dividend statements (if applicable) and annual reports. You can make a standing election to receive some or all of your shareholder communications in physical or electronic form.

To review or update your current communication preference simply logon to our share registry’s website here. You will need your portfolio log in details or your Shareholder Reference Number (SRN) or Holder Identification Number (HIN). Once logged in, select the ‘communications’ tab at the top of the page.

If at any time you require an additional copy of a communication, or you need more information about the options available to you, you may contact Link Market Services via email at LMSComms@linkmarketservices.com.au